Suppr超能文献

TAC 评分比 BCLC 更能预测肝癌切除术后的生存率。

TAC score better predicts survival than the BCLC following resection of hepatocellular carcinoma.

机构信息

Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, Ohio, USA.

School of Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil.

出版信息

J Surg Oncol. 2023 Mar;127(3):374-384. doi: 10.1002/jso.27116. Epub 2022 Oct 4.

Abstract

BACKGROUND

Heterogeneity in hepatocellular carcinoma (HCC) still exists within the Barcelona clinic liver cancer (BCLC) subcategories. We developed a simple model to better discriminate and predict prognosis following resection.

METHODS

Patients who underwent curative-intent resection for HCC were identified from a multi-institutional database. Predictive factors of survival were identified to develop TAC (tumor burden score [TBS], alpha-fetoprotein [AFP], Child-Pugh CP]) score.

RESULTS

Among 1435 patients, median TBS was 5.1 (interquartile range [IQR]: 3.2-8.1), median AFP was 18.3 ng/ml (IQR 4.0-362.5), and 1391 (96.9%) patients were classified as CP-A. Factors associated with overall survival (OS) included TBS (low: referent; medium: HR 2.26, 95% CI: 1.73-2.96; high: HR = 3.35, 95% CI: 2.22-5.07), AFP (<400 ng/ml: referent; >400 ng/ml: HR = 1.56, 95% CI: 1.27-1.92), and CP (A: referent; B: HR = 1.81, 95% CI: 1.12-2.92) (all p < 0.05). A simplified risk score demonstrated superior concordance index, Akaike information criteria, homogeneity, and area under the curve versus BCLC (0.620 vs. 0.541; 5484.655 vs. 5536.454; 60.099 vs. 16.194; 0.62 vs. 0.55, respectively), and further stratified patients within BCLC groups relative to OS (BCLC 0, very low: 86.8%, low: 47.8%) (BCLC A, very low: 79.7%, low: 68.1%, medium: 52.5%, high: 35.6%) (BCLC B, low: 59.8%, medium: 43.7%, high: N/A).

CONCLUSION

TAC is a simple, holistic score that consistently outperformed BCLC relative to discrimination power and prognostication following resection of HCC.

摘要

背景

在巴塞罗那临床肝癌(BCLC)亚类中,肝细胞癌(HCC)仍然存在异质性。我们开发了一种简单的模型,以更好地区分和预测手术后的预后。

方法

从多机构数据库中确定接受根治性切除 HCC 的患者。确定生存预测因素以开发 TAC(肿瘤负担评分[TBS]、甲胎蛋白[AFP]、Child-Pugh CP])评分。

结果

在 1435 名患者中,中位 TBS 为 5.1(四分位距[IQR]:3.2-8.1),中位 AFP 为 18.3ng/ml(IQR 4.0-362.5),1391(96.9%)名患者被归类为 CP-A。与总生存(OS)相关的因素包括 TBS(低:参照;中:HR 2.26,95%CI:1.73-2.96;高:HR=3.35,95%CI:2.22-5.07)、AFP(<400ng/ml:参照;>400ng/ml:HR=1.56,95%CI:1.27-1.92)和 CP(A:参照;B:HR=1.81,95%CI:1.12-2.92)(均 p<0.05)。简化风险评分显示出更高的一致性指数、Akaike 信息准则、同质性和曲线下面积,优于 BCLC(0.620 与 0.541;5484.655 与 5536.454;60.099 与 16.194;0.62 与 0.55),并进一步分层了 BCLC 组内的患者相对于 OS(BCLC 0,极低:86.8%,低:47.8%)(BCLC A,极低:79.7%,低:68.1%,中:52.5%,高:35.6%)(BCLC B,低:59.8%,中:43.7%,高:无)。

结论

TAC 是一种简单的整体评分,与 HCC 切除后的区分能力和预后相比,始终优于 BCLC。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a39d/10091702/9e9306e1c464/JSO-127-374-g002.jpg

相似文献

1
TAC score better predicts survival than the BCLC following resection of hepatocellular carcinoma.
J Surg Oncol. 2023 Mar;127(3):374-384. doi: 10.1002/jso.27116. Epub 2022 Oct 4.
2
Tumor Burden Score and Serum Alpha-fetoprotein Subclassify Intermediate-Stage Hepatocellular Carcinoma.
J Gastrointest Surg. 2022 Dec;26(12):2512-2521. doi: 10.1007/s11605-022-05469-9. Epub 2022 Sep 28.
4
Hepatocellular carcinoma tumour burden score to stratify prognosis after resection.
Br J Surg. 2020 Jun;107(7):854-864. doi: 10.1002/bjs.11464. Epub 2020 Feb 14.
6
Prediction of tumor recurrence by α-fetoprotein model after curative resection for hepatocellular carcinoma.
Eur J Surg Oncol. 2021 Mar;47(3 Pt B):660-666. doi: 10.1016/j.ejso.2020.10.017. Epub 2020 Oct 15.
8
External validation of a simplified BCLC staging system for early hepatocellular carcinoma.
Eur J Surg Oncol. 2013 Aug;39(8):850-7. doi: 10.1016/j.ejso.2013.05.001. Epub 2013 May 29.
9
A preoperative model to predict overall survival in patients with hepatoma undergoing resection.
Am J Surg. 2024 Nov;237:115778. doi: 10.1016/j.amjsurg.2024.115778. Epub 2024 May 23.

本文引用的文献

1
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.
J Hepatol. 2022 Mar;76(3):681-693. doi: 10.1016/j.jhep.2021.11.018. Epub 2021 Nov 19.
4
Hepatocellular carcinoma.
Nat Rev Dis Primers. 2021 Jan 21;7(1):6. doi: 10.1038/s41572-020-00240-3.
5
Prediction of tumor recurrence by α-fetoprotein model after curative resection for hepatocellular carcinoma.
Eur J Surg Oncol. 2021 Mar;47(3 Pt B):660-666. doi: 10.1016/j.ejso.2020.10.017. Epub 2020 Oct 15.
6
Recurrence Patterns and Outcomes after Resection of Hepatocellular Carcinoma within and beyond the Barcelona Clinic Liver Cancer Criteria.
Ann Surg Oncol. 2020 Jul;27(7):2321-2331. doi: 10.1245/s10434-020-08452-3. Epub 2020 Apr 13.
7
Hepatocellular carcinoma tumour burden score to stratify prognosis after resection.
Br J Surg. 2020 Jun;107(7):854-864. doi: 10.1002/bjs.11464. Epub 2020 Feb 14.
9
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.
J Hepatol. 2018 Jul;69(1):182-236. doi: 10.1016/j.jhep.2018.03.019. Epub 2018 Apr 5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验